Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead Licenses Remdesivir To Five Firms

Cipla, Ferozsons, Hetero, Jubilant And Mylan Get Rights

Executive Summary

Gilead has announced a raft of licensing agreements with five generics firms to manufacture potential COVID-19 treatment remdesivir for distribution in 127 countries.

You may also be interested in...



Gilead Scales Up Remdesivir Production To Meet Indian Demand

To tackle the increase in demand for remdesivir in India amidst the second wave of COVID-19, Gilead Sciences is helping local licensees to scale up production of the product, including by providing API supplies. The company is also donating at least 450,000 vials of the Veklury brand “to help address the immediate needs of Indian patients.”

India Remdesivir Saga: Exports Barred, Ramp Up Plans And Panic

India stops remdesivir exports amid steep surge in COVID-19 cases, while licensees of Gilead’s antiviral take multiple measures to ramp up production to meet local demand. One badly affected state stresses the need to stem panic given the limitations of the treatment, even as some non-licensees of the drug apparently seek to contribute to supplies.

India’s Saptagir Partners With Jubilant On Remdesivir

India’s Saptagir Laboratories has struck a deal with Jubilant Pharma to manufacture the ingredient for COVID-19 emergency treatment remdesivir. Meanwhile, following in the footsteps of Cipla, Hetero, Mylan and Zydus, Dr Reddy’s has launched its version of remdesivir for the Indian market under a licensing deal with Gilead.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149889

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel